Michael Lim, MD
Neurosurgery · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lim’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A76130 · Current
Licensed to practise in California · since 2001 · expires 2029-01-31 · Johns Hopkins University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Maryland D0065890Physician · since 2007 · expires 2028-09-30Specialty on the licence: Neurological SurgeryTold the state board they are board certified.ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$127,382
Medicare paid this office $127,382 for 160 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of skull base bone for exploration or release of cranial nerves | 37 | $63,537 | $1,717 |
| Computer-assisted creation of growth of face nerve | 15 | $14,975 | $749 |
| Computer-assisted procedure inside brain | 39 | $7,463 | $191 |
| Use of operating microscope | 39 | $6,889 | $177 |
| New patient visit (45+ min) | 37 | $5,512 | $149 |
See all 9 services
| Removal of skull base bone for exploration or release of cranial nerves | 37 | $63,537 | $1,717 |
| Computer-assisted creation of growth of face nerve | 15 | $14,975 | $749 |
| Computer-assisted procedure inside brain | 39 | $7,463 | $191 |
| Use of operating microscope | 39 | $6,889 | $177 |
| New patient visit (45+ min) | 37 | $5,512 | $149 |
| Return visit (30+ min) | 35 | $5,099 | $119 |
| New patient visit (45+ min) | 39 | $4,663 | $120 |
| Return visit (30+ min) | 16 | $1,321 | $73 |
| Short return visit (20+ min) | 13 | $1,148 | $88 |
Who their Medicare patients are
160 Original Medicare patients in 2024. Average age 72 · Under 65 9% · 85 and older 9% · Women 69% · Also on Medicaid 14% · Health risk score 1.10. At or below the middle of the specialty; the typical neurosurgery clinician is at 1.46.
Conditions among them: High blood pressure 64% · Coronary heart disease 27% · Depression 24% · Chronic kidney disease 18% · Cancer 17% · Diabetes 16% · Atrial fibrillation 14% · Stroke 11% · Heart failure 9% · COPD 9%.
The office billed $816,303, Medicare allowed $161,911 and paid $127,382; for 323 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 160 | 323 | 72 | 1.10 | $816,303 | $127,382 |
| 2023 | 113 | 233 | 72 | 1.13 | $730,790 | $111,048 |
| 2022 | 81 | 175 | 72 | 1.12 | $590,063 | $86,459 |
| 2021 | 65 | 151 | 74 | 1.07 | $468,791 | $70,375 |
| 2020 | 217 | 429 | 72 | 1.60 | $1,533,877 | $220,868 |
| 2019 | 422 | 834 | 71 | 1.61 | $2,800,515 | $396,634 |
| 2018 | 423 | 888 | 72 | 1.61 | $3,205,050 | $420,153 |
| 2017 | 382 | 822 | 71 | 1.44 | $2,913,683 | $392,823 |
| 2016 | 339 | 730 | 71 | 1.41 | $2,507,960 | $342,886 |
| 2015 | 311 | 725 | 71 | 1.49 | $2,754,803 | $355,874 |
| 2014 | 344 | 731 | 71 | 1.47 | $2,632,556 | $326,963 |
| 2013 | 280 | 561 | 70 | 1.33 | $1,889,849 | $245,695 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Removal of skull base bone for exploration or release of cranial nerves | 22 | $37,746 | $1,716 |
| Computer-assisted procedure inside brain | 33 | $6,407 | $194 |
| New patient visit (45+ min) | 45 | $5,278 | $117 |
| Use of operating microscope | 28 | $4,996 | $178 |
| Return visit (30+ min) | 31 | $2,981 | $88 |
| Short return visit (20+ min) | 13 | $854 | $57 |
2022: 5 services
| Removal of skull base bone for exploration or release of cranial nerves | 25 | $44,007 | $1,760 |
| Computer-assisted procedure inside brain | 27 | $5,354 | $198 |
| Use of operating microscope | 27 | $4,944 | $183 |
| New patient visit (45+ min) | 39 | $4,628 | $119 |
| Return visit (30+ min) | 16 | $1,476 | $87 |
2021: 5 services
| Removal of skull base bone for exploration or release of cranial nerves | 13 | $22,981 | $1,768 |
| New patient visit (45+ min) | 33 | $4,041 | $122 |
| Computer-assisted procedure inside brain | 19 | $3,857 | $203 |
| Use of operating microscope | 18 | $3,377 | $188 |
| Return visit (30+ min) | 19 | $2,034 | $92 |
2020: 13 services
| Removal of skull base bone for exploration or release of cranial nerves | 23 | $42,199 | $1,835 |
| Removal of skull bone for removal of growth of upper brain | 14 | $29,971 | $1,998 |
| Computer-assisted creation of growth of face nerve | 31 | $25,471 | $749 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 20 | $20,461 | $930 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 13 | $16,474 | $1,267 |
| Computer-assisted procedure inside brain | 49 | $10,440 | $209 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 13 | $7,039 | $201 |
| Use of operating microscope | 28 | $5,405 | $186 |
| New patient visit (30+ min) | 37 | $2,190 | $59 |
| Telephone medical discussion with physician, 11-20 minutes | 26 | $1,263 | $45 |
| Short return visit (20+ min) | 41 | $1,246 | $30 |
| Short return visit (20+ min) | 11 | $485 | $44 |
| Telephone medical discussion with physician, 5-10 minutes | 16 | $341 | $21 |
2019: 12 services
| Removal of skull base bone for exploration or release of cranial nerves | 39 | $73,632 | $1,888 |
| Removal of skull bone for removal of growth of upper brain | 24 | $54,914 | $2,197 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 50 | $54,292 | $936 |
| Computer-assisted creation of growth of face nerve | 49 | $50,810 | $782 |
| Computer-assisted procedure inside brain | 83 | $18,436 | $219 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 14 | $17,963 | $1,283 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 26 | $13,744 | $205 |
| New patient visit (30+ min) | 153 | $9,421 | $62 |
| Use of operating microscope | 47 | $8,829 | $188 |
| Short return visit (20+ min) | 163 | $7,414 | $40 |
| Return visit (30+ min) | 12 | $769 | $64 |
| New patient visit (15+ min) | 19 | $675 | $36 |
2018: 13 services
| Removal of skull bone for removal of growth of upper brain | 35 | $73,471 | $2,041 |
| Removal of skull base bone for exploration or release of cranial nerves | 34 | $62,123 | $1,827 |
| Computer-assisted creation of growth of face nerve | 57 | $50,803 | $782 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 39 | $41,444 | $921 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 26 | $31,284 | $1,203 |
| Computer-assisted procedure inside brain | 99 | $21,552 | $216 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 21 | $12,963 | $203 |
| New patient visit (30+ min) | 156 | $9,641 | $62 |
| Use of operating microscope | 44 | $8,591 | $195 |
| Short return visit (20+ min) | 159 | $7,588 | $40 |
| Return visit (30+ min) | 25 | $1,615 | $65 |
| New patient visit (15+ min) | 16 | $646 | $40 |
| New patient visit (10+ min) | 12 | $228 | $19 |
2017: 12 services
| Removal of skull base bone for exploration or release of cranial nerves | 38 | $68,528 | $1,803 |
| Removal of skull bone for removal of growth of upper brain | 31 | $66,401 | $1,953 |
| Computer-assisted creation of growth of face nerve | 58 | $58,784 | $794 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 32 | $36,557 | $914 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 15 | $19,890 | $1,243 |
| Computer-assisted procedure inside brain | 85 | $18,557 | $211 |
| Computer-assisted radiosurgery of growth of spine, first growth | 11 | $13,192 | $1,015 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 17 | $10,181 | $200 |
| New patient visit (30+ min) | 143 | $8,766 | $61 |
| Use of operating microscope | 46 | $8,558 | $186 |
| Short return visit (20+ min) | 142 | $7,259 | $41 |
| New patient visit (15+ min) | 18 | $765 | $43 |
2016: 12 services
| Removal of skull bone for removal of growth of upper brain | 33 | $63,689 | $1,820 |
| Removal of skull base bone for exploration or release of cranial nerves | 36 | $63,511 | $1,764 |
| Computer-assisted creation of growth of face nerve | 56 | $58,747 | $734 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 24 | $29,842 | $904 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 16 | $20,951 | $1,232 |
| Computer-assisted procedure inside brain | 80 | $16,947 | $204 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 13 | $7,704 | $198 |
| New patient visit (30+ min) | 121 | $7,628 | $63 |
| Use of operating microscope | 44 | $7,553 | $172 |
| Short return visit (20+ min) | 126 | $6,005 | $39 |
| Return visit (30+ min) | 15 | $978 | $65 |
| New patient visit (15+ min) | 11 | $420 | $38 |
2015: 13 services
| Computer-assisted radiosurgery of simple growth of brain, first growth | 42 | $53,724 | $911 |
| Computer-assisted creation of growth of face nerve | 55 | $48,749 | $786 |
| Removal of skull base bone for exploration or release of cranial nerves | 27 | $43,822 | $1,623 |
| Removal of skull bone for removal of growth of upper brain | 23 | $43,453 | $1,811 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 21 | $27,359 | $1,244 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 28 | $16,581 | $200 |
| Computer-assisted procedure inside brain | 73 | $15,881 | $212 |
| New patient visit (30+ min) | 104 | $6,659 | $64 |
| Use of operating microscope | 32 | $5,139 | $161 |
| Short return visit (20+ min) | 95 | $4,601 | $40 |
| Return visit (30+ min) | 12 | $718 | $60 |
| New patient visit (15+ min) | 15 | $624 | $42 |
| Short return visit | 17 | $321 | $19 |
2014: 13 services
| Computer-assisted creation of growth of face nerve | 62 | $53,913 | $739 |
| Removal of skull bone for removal of growth of upper brain | 29 | $51,741 | $1,784 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 40 | $42,643 | $820 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 26 | $31,972 | $1,184 |
| Removal of skull base bone for exploration or release of cranial nerves | 15 | $27,160 | $1,811 |
| Computer-assisted radiosurgery of growth of spine, first growth | 14 | $14,342 | $956 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 27 | $12,495 | $184 |
| Computer-assisted procedure inside brain | 52 | $10,525 | $202 |
| New patient visit (30+ min) | 127 | $7,773 | $61 |
| Short return visit (20+ min) | 110 | $5,461 | $40 |
| Use of operating microscope | 20 | $3,747 | $187 |
| Return visit (30+ min) | 14 | $915 | $65 |
| Short return visit | 33 | $667 | $20 |
2013: 11 services
| Computer-assisted creation of growth of face nerve | 64 | $55,739 | $733 |
| Removal of skull bone for removal of growth of upper brain | 21 | $38,061 | $1,812 |
| Computer-assisted radiosurgery of simple growth of brain, first growth | 28 | $32,193 | $825 |
| Removal of skull base bone for exploration or release of cranial nerves | 17 | $28,707 | $1,689 |
| Computer-assisted biopsy, aspiration, or excision of growth of brain using ct and/or mri guidance | 13 | $15,355 | $1,181 |
| Computer-assisted radiosurgery of complex growth of brain, first growth | 13 | $15,309 | $1,178 |
| Computer-assisted procedure inside brain | 40 | $7,982 | $200 |
| New patient visit (30+ min) | 131 | $7,542 | $58 |
| Computer-assisted radiosurgery of simple growth of brain, each additional growth | 12 | $6,113 | $170 |
| Short return visit (20+ min) | 91 | $4,104 | $38 |
| Use of operating microscope | 18 | $3,311 | $184 |
Money from drug and device companies
$71,809 in 2025
| 2025 | 6 | 21 | $50,868 | $71,809 |
| 2024 | 1 | 25 | $28,125 | $32,493 |
| 2023 | 4 | 67 | $47,840 | $59,660 |
| 2022 | 7 | 71 | $65,660 | $84,783 |
| 2021 | 8 | 26 | $18,293 | $23,636 |
| 2020 | 7 | 16 | $9,750 | $10,980 |
| 2019 | 7 | 39 | $24,200 | $41,694 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Stryker | Medpor Titan | $31,930 | 9 payments
|
| Novocure | Optune Gio | $20,314 | 2 payments
|
| Merck Sharp & Dohme | None | $18,308 | 6 payments
|
| Regeneron Pharmaceuticals | None | $1,142 | 2 payments
|
| Brainlab | Brainlab, Inc. | $98 | 1 payment
|
| Apellis Pharmaceuticals | None | $17 | 1 payment
|
See all 21 published payments
| Novocure | Travel · 2025-11-25 | Optune Gio | $11,187 |
| Regeneron Pharmaceuticals | Consulting · 2025-11-21 | None | $381 |
| Regeneron Pharmaceuticals | Consulting · 2025-11-21 | None | $761 |
| Brainlab | Meals · 2025-10-28 | Brainlab, Inc. | $98 |
| Stryker | Consulting · 2025-10-24 | Universal Neuro 3 | $10,500 |
| Stryker | Meals · 2025-10-24 | Universal Neuro 3 | $15 |
| Stryker | Meals · 2025-10-24 | Universal Neuro 3 | $41 |
| Stryker | Meals · 2025-10-13 | Sonopet Iq | $126 |
| Novocure | Consulting · 2025-09-25 | Optune Gio | $9,127 |
| Apellis Pharmaceuticals | Meals · 2025-07-17 | None | $17 |
| Merck Sharp & Dohme | Travel · 2025-06-23 | None | $150 |
| Merck Sharp & Dohme | Paid to speak or teach · 2025-06-23 | None | $9,600 |
| Merck Sharp & Dohme | Travel · 2025-06-14 | None | $49 |
| Merck Sharp & Dohme | Meals · 2025-06-14 | None | $42 |
| Merck Sharp & Dohme | Travel · 2025-06-13 | None | $8,349 |
| Merck Sharp & Dohme | Travel · 2025-06-13 | None | $118 |
| Stryker | Consulting · 2025-05-08 | Medpor Titan | $9,750 |
| Stryker | Education · 2025-05-05 | Universal Neuro 3 | $416 |
| Stryker | Meals · 2025-04-25 | Core | $175 |
| Stryker | Meals · 2025-04-22 | Na | $158 |
| Stryker | Consulting · 2025-03-28 | Medpor Titan | $10,750 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $32,493
| Stryker | Universal Neuro 3 | $32,493 | 25 payments
|
2023: $59,660
| Stryker | Medpor Titan | $46,428 | 27 payments
|
| Novocure | Optune | $8,743 | 15 payments
|
| E.R. Squibb & Sons L.L.C. | None | $2,720 | 16 payments
|
| ClearPoint Neuro | Clearpoint | $1,770 | 4 payments
|
2022: $84,783
| Stryker | Universal Neuro 3 | $65,634 | 49 payments
|
| Novocure | Optune | $7,690 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $5,942 | 7 payments
|
| Brainlab | Image Guided Surgical Device | $3,306 | 8 payments
|
| Insightec | Exablate | $2,000 | 1 payment
|
| Siemens Medical Solutions USA | Edge | $141 | 1 payment
|
| Incyte | Monjuvi | $70 | 1 payment
|
2021: $23,636
| Stryker | Vsp System, Vsp Cranial | $12,501 | 13 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $4,403 | 5 payments
|
| Novocure | None | $4,029 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $2,250 | 1 payment
|
| Regeneron Pharmaceuticals | None | $250 | 1 payment
|
| Baxter Healthcare | No Related Product | $157 | 2 payments
|
| Zap Surgical Systems | Zap-X Mv Imager | $34 | 1 payment
|
| Evofem Biosciences | Phexxi | $12 | 1 payment
|
2020: $10,980
| Celgene | None | $5,000 | 1 payment
|
| Stryker | Neuro Fixation | $2,673 | 8 payments
|
| InSightec | None | $2,000 | 1 payment
|
| Celularity | None | $500 | 1 payment
|
| Zap Surgical Systems | Zap-X | $500 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $263 | 2 payments
|
| Exeltis USA | Slynd | $44 | 2 payments
|
2019: $41,694
| Stryker | Neuro | $21,107 | 12 payments
|
| E.R. Squibb & Sons L.L.C. | None | $19,129 | 22 payments
|
| Evolution Surgical | None | $884 | 1 payment
|
| Elekta | Unity | $355 | 1 payment
|
| Abiomed | Impella | $175 | 1 payment
|
| Incyte | None | $24 | 1 payment
|
| Exeltis USA | Vitafol Ultra | $20 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Biohaven Pharmaceutical Holding Company Ltd. · A Phase 2 Double Blind Placebo Controlled Crossover Trial of Bhv-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia · 2022 | Their institution | $65,542 |
| Kyowa Kirin Pharmaceutical Development, Inc · 2021 | Their institution | $60,820 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Unmethylated Mgmt Nivo Mono Rt · 2019 | Their institution | $47,547 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2023 | Their institution | $37,568 |
| E.R. Squibb & Sons, L.L.C. · Phase III 1l Gbm Methylated Nivo Mono Chemo Rt · 2019 | Their institution | $35,973 |
| E.R. Squibb & Sons, L.L.C. · Phase III Gbm 2l Registrational · 2019 | Their institution | $15,430 |
| AstraZeneca Pharmaceuticals LP · Medi4736 Ph 2 Ludwig Temozolom. Combo Gbm · 2019 | Their institution | $15,370 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2024 | Their institution | $8,669 |
| AstraZeneca Pharmaceuticals LP · Medi4736 Ph 2 Ludwig Temozolom. Combo Gbm · 2020 | Their institution | $6,830 |
| Biohaven Pharmaceuticals, Inc. · A Phase 2 Double Blind Placebo Controlled Crossover Trial of Bhv-3000 (Rimegepant) for Treatment Refractory Trigeminal Neuralgia · 2021 | Their institution | $4,479 |
| PFIZER INC. · Bhv3000202 Phase 2 A Doubleblind Placebo Controlled Crossover Trial of Bhv3000 Rimegepant for Treatment Refractory Trigeminal Neuralgia · 2023 | Their institution | $2,680 |
| Incyte Corporation · A Phase 2, Open-Label, Single-Arm, Multicenter Study To Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma Or Other Primary Central Nervous System Tumors Harboring Activating Fgfr1-3 Alterations (Fight-209) · 2022 | Their institution | $824 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1225240286
- Licence
- CA A76130, MD D65890California A76130: Current · expires 2029-01-31Maryland D0065890: Active
- Trained
- Johns Hopkins University School of Medicine, 2000
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- MD 014188700
- Taxonomy
- Federal specialty code 207T00000X (207T00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-05-03
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.